News
-
-
PRESS RELEASE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected -
-
-
-
-
-
-
-
PRESS RELEASE
Q2 Metals Drills 120.3 M at 1.72% Li2O including 19.0 M at 2.06% in First Assays Reported from its Spring 2024 Drill Campaign at the Cisco Lithium Property, James Bay, Quebec, Canada
Q2 Metals announces strong analytical results from inaugural drilling campaign at Cisco Lithium Property in Quebec, Canada. Results include wide intervals of high-grade lithium mineralization